Clinical Trial Update: A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 trial compares a single dose of SB-681323 to prednisolone in rheumatoid arthritis, using a protein biomarker as an indicator of disease activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Prednisolone (Prednisolone)
• SB-681323

Snippet

Sponsor: GlaxoSmithKline | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: COMPLETED